© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
December 08, 2022
“While there’s benefit in improving access, there’s also potential for harm when providers fail to follow evidence-based guidelines, or when the benefits and risks of treatment are not appropriately communicated," said Joshua A. Halpern, MD.
August 04, 2022
Kyzatrex is an oral testosterone replacement therapy for the treatment of adult males with conditions associated with hypogonadism.
June 09, 2022
Testosterone undecanoate (Tlando), an oral testosterone replacement therapy, was approved in March 2022 for the treatment of men with hypogonadism.
March 29, 2022
The pivotal trial supporting approval of the oral testosterone undecanoate was Study 16-002, which included 95 hypogonadal males.
November 11, 2021
"We didn't see any clinically significant changes on the prostate gland, which is very important for the urologists who see people who have prostate cancer or prostate enlargement," says Ronald Swerdloff, MD.
July 26, 2021
Researchers from the FDA’s Center for Drug Evaluation and Research determined that the benefits of androgen receptor inhibitors outweighed the risks in men aged ≥80 years with nonmetastatic castration-resistant prostate cancer.
July 04, 2021
Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.
July 02, 2021
"Early data suggest that low testosterone levels increase the risk of developing severe disease and that testosterone supplementation may provide benefit for men who are infected by the SARS-CoV-2 virus," says Mohit Khera, MD, MBA, MPH.
July 01, 2021
Researchers suggest diet may play important role in male reproductive health.
June 23, 2021
“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.